ELN-DAVID recommendations for NGS-based <i>FLT3</i> -ITD MRD testing for patients with acute myeloid leukemia
Abstract
Abstract FLT3-internal tandem duplication measurable residual disease testing for patients in remission from acute myeloid leukemia is now recommended by the recently updated clinical standard-of-care guidelines. This companion technical note provides important laboratory and clinical recommendations regarding such testing.
Article Details
Authors (21)
Christopher S. Hourigan
1Fralin Biomedical Research Institute, Virginia Tech Fralin Biomedical Research Institute Cancer Research Center, Washington, DC
Lisanne Beugelink
2Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands
Jad Othman
3The University of Sydney, Sydney, Australia
Gege Gui
1Fralin Biomedical Research Institute, Virginia Tech Fralin Biomedical Research Institute Cancer Research Center, Washington, DC
Adam Ivey
6Alfred Hospital, Melbourne, VIC, Australia
Richard Dillon
5King's College London, London, United Kingdom
Christian Thiede
7University Hospital, Dresden University of Technology, Dresden, Germany
Mark J. Levis
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Laura W. Dillon
1Fralin Biomedical Research Institute, Virginia Tech Fralin Biomedical Research Institute Cancer Research Center, Washington, DC
Andrew H. Wei
Ing Soo Tiong
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
Sun Loo
6Alfred Hospital, Melbourne, VIC, Australia
Konstanze Döhner
12University Hospital of Ulm, Ulm, Germany
Isabell Arnhardt
13Hannover Medical School, Hannover, Germany
Artur Kowalik
14Holy Cross Cancer Center, Kielce, Poland
Nicola Potter
5King's College London, London, United Kingdom
Dennis Dong Hwan Kim
16Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada
Claude Preudhomme
Unité Mixte de Recherche (UMR) 9020-UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Institut de Recherche contre le Cancer de Lille, University of Lille, CNRS, Inserm, Centre Hospitalier Universitaire Lille, Lille, France
Nicolas Duployez
Unité Mixte de Recherche (UMR) 9020-UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Institut de Recherche contre le Cancer de Lille, University of Lille, CNRS, Inserm, Centre Hospitalier Universitaire Lille, Lille, France
Michael Heuser
Peter J. M. Valk
2Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands